Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lee Schwartzberg

Showing results (91-100 of 112) with videos related to

Pageof 12
Sort By:
Breast Cancer Research and Treatment|January 21, 2018
Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG)Jame Abraham, Humberto Caldera, Robert Coleman, et al.
Future Oncology (London, England)|March 19, 2025
Nausea and vomiting in an evolving anticancer treatment landscape: long-delayed and emetogenic antibody-drug conjugatesYeon Hee Park, Giampaolo Bianchini, Javier Cortés, et al.
Clinical Breast Cancer|March 7, 2020
A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast CancerReshma Mahtani, Frankie-Ann Holmes, Sunil Badve, et al.
Breast Cancer Research and Treatment|May 2, 2019
Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy aloneIvana Sestak, Miguel Martín, Peter Dubsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2008
Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE StudyHoward S Hochster, Lowell L Hart, Ramesh K Ramanathan, et al.
The Oncologist|December 8, 2020
Avoidable Acute Care Use Associated with Nausea and Vomiting Among Patients Receiving Highly Emetogenic Chemotherapy or OxaliplatinRudolph M Navari, Kathryn J Ruddy, Thomas W LeBlanc, et al.
Breast (Edinburgh, Scotland)|March 29, 2025
Real-world risk of recurrence and treatment outcomes with adjuvant endocrine therapy in patients with stage II-III HR+/HER2- early breast cancerJoyce O'Shaughnessy, Sara M Tolaney, Denise A Yardley, et al.
Oncotarget|April 7, 2016
Analysis of tumor template from multiple compartments in a blood sample provides complementary access to peripheral tumor biomarkersWilliam M Strauss, Chris Carter, Jill Simmons, et al.
Clinical Breast Cancer|February 5, 2020
Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG)Muaiad Kittaneh, Sunil Badve, Humberto Caldera, et al.
Cancer|October 15, 2013
TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: A randomized phase 1b/2 trialCharles S Fuchs, Marwan Fakih, Lee Schwartzberg, et al.
Pageof 12

Showing results (91-100 of 112) with videos related to

Sort By:
Pageof 12
Breast Cancer Research and Treatment|January 21, 2018
Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG)Jame Abraham, Humberto Caldera, Robert Coleman, et al.
Future Oncology (London, England)|March 19, 2025
Nausea and vomiting in an evolving anticancer treatment landscape: long-delayed and emetogenic antibody-drug conjugatesYeon Hee Park, Giampaolo Bianchini, Javier Cortés, et al.
Clinical Breast Cancer|March 7, 2020
A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast CancerReshma Mahtani, Frankie-Ann Holmes, Sunil Badve, et al.
Breast Cancer Research and Treatment|May 2, 2019
Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy aloneIvana Sestak, Miguel Martín, Peter Dubsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2008
Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE StudyHoward S Hochster, Lowell L Hart, Ramesh K Ramanathan, et al.
The Oncologist|December 8, 2020
Avoidable Acute Care Use Associated with Nausea and Vomiting Among Patients Receiving Highly Emetogenic Chemotherapy or OxaliplatinRudolph M Navari, Kathryn J Ruddy, Thomas W LeBlanc, et al.
Breast (Edinburgh, Scotland)|March 29, 2025
Real-world risk of recurrence and treatment outcomes with adjuvant endocrine therapy in patients with stage II-III HR+/HER2- early breast cancerJoyce O'Shaughnessy, Sara M Tolaney, Denise A Yardley, et al.
Oncotarget|April 7, 2016
Analysis of tumor template from multiple compartments in a blood sample provides complementary access to peripheral tumor biomarkersWilliam M Strauss, Chris Carter, Jill Simmons, et al.
Clinical Breast Cancer|February 5, 2020
Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG)Muaiad Kittaneh, Sunil Badve, Humberto Caldera, et al.
Cancer|October 15, 2013
TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: A randomized phase 1b/2 trialCharles S Fuchs, Marwan Fakih, Lee Schwartzberg, et al.
Pageof 12